Journal of obstetrics and women's diseasesJournal of obstetrics and women's diseases1684-04611683-9366Eco-Vector129410.17816/JOWD613109-114Research ArticleFeatures of the gene polymorphism of estrogen and progesterone receptors in women with uterine leiomyomaOsinovskayaNatalya SergeevnaPhD, senior research fellow of the laboratory of prenatal diagnostics of congenial and hereditary diseasesnatosinovskaya@mail.ruIvaschenkoTatyana EduardovnaDr. Sci, Prof., Leading Researcher of the laboratory of prenatal diagnostics of congenial and hereditary diseases-DzhemlikhanovaLyailya KharryasovnaPhD, associate professor, Faculty of Medicine, Department of Obstetrics, Gynecology and Reproductology-BaranovVladislav Sergeevichhead of lab.for Prenatal Diagnosis, MD, professor-TkachenkoAntonina Nicolaevnastudent (6-th cours), Faculty of Medicine, Department of Obstetrics, Gynecology and Reproductology-SultanovIskender Yuryevichassistant of laboratory of prenatal diagnostics of congenial and hereditary diseases-Ott Research Institute of Obstetrics and Gynecology, RAMSSt. Petersburg State UniversityD. O. Ott Institute of Obstetrics and Gynecology1506201261310911415062012Copyright © 2012, Osinovskaya N.S., Ivaschenko T.E., Dzhemlikhanova L.K., Baranov V.S., Tkachenko A.N., Sultanov I.Y.2012Uterine Leiomyoma (Leiomyoma) (LM) — benign and most common (incidence 20–45 %) hormone-dependent tumors of female genital organs. Comparative analysis of frequencies of polymorphic variants of genes of estrogen receptor (ERα) and progesterone receptor (PGR) in patients with LM and the population samples was conducted in this work. Also it was investigated their association with clinical manifestation of hyperplastic processes of the female reproductive system. It was founded that the development of LM are not associated with individual polymorphic variants of genes of estrogen receptor and progesterone receptor. This fact does not include their participation in the development of proliferative and hyperplastic processes of the myometriumERαPGRleiomyomahormone receptorsestrogene, progesteroneERαPGRлейомиома маткирецепторы гормоновэстрогенпрогестерон[1. Антропова Е. Ю., Тухватуллина Л. М. Эмболизация маточных артерий в лечении больных миомой матки // Трудный пациент. — 2006. — № 9. — С. 33–35.][2. Вихляева Е. М. Молекулярно-генетические детерминанты опухолевого роста и обоснование современной стратегии при лейомиоме матки // Вопросы онкологии. — 2001. — Т. 47, № 2–3. — С. 215–216.][3. Иммуногистохимические особенности экспрессии сигнальных молекул в миометрии и эндометрии больных с сочетанными гиперпластическими процессами матки / Смирнова М. Ю. [и др.] // Науч. ведомости Белгородск. гос. ун-та. Сер. Медицина. Фармация. — 2011. — Вып. 13/1, Т. 4, № 99. — С. 11–16.][4. Современные представления о молекулярно-генетических основах миомы матки / Егорова О. В. [и др.] // Медицинская генетика. — 2007. — Т. 6, №.9. — С. 11–16.][5. Шиляев А. Ю. Лейомиома матки // Гинекология. — 2005. — Т. 7,№ 1. — С. 65–70.][6. A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells / Chen W. [et al.] // Clin. Endocrinol. Metab. — 2006. — Vol. 1, № 4. — P. 1296–1304.][7. Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen / Migliaccio A. [et al.] // EMBO J. — 1998. — Vol. 17. — P. 2008–2018.][8. Analysis of estrogen receptor (ERalpha and ERbeta) and progesterone receptor (PR) polymorphisms in uterine leiomyomas / Massart F. [et al.] // Med. Sci. Monit. — 2003. — Vol. 9, № 1. — Р. 25–30.][9. Association of 5' estrogen receptor alpha gene polymorphisms with bone mineral density, vertebral bone area and fracture risk / van Meurs J. B. [et al.] // Hum. Mol. Genet. — 2003. — Vol. 12, № 14. — Р. 1745–1754.][10. Association of bone mineral density with polymorphism of the estrogen receptor gene / Kobayashi S. [et al.] // J. Bone Miner. Res. — 1996. — Vol. 11. — P. 306–311.][11. BRCA2 mutations in primary breast and ovarian cancers / Lancaster J. M. [et al.] // Nature Genetics. — 1996. — Vol. 13. — P. 238–240.][12. Endocrine profile associated with estrogen and progesterone receptors in leiomyoma and normal myometrium / Sadan O. [et al.] // Gynecol. Endocrinol. — 1990. — Vol. 4. — Р. 133–142.][13. Estrogen metabolite 2-methoxyestradiol induces apoptosis and inhibits cell proliferation and collagen production in rat and human leiomyoma cells: a potential medicinal treatment for uterine fibroids / Salama S. A. [et al.] // J. Soc. Gynecol. Investig. — 2006. — Vol. 13, № 8. — P. 542–550][14. Flake G. P., Andersen J., Dixon D. Etiology and pathogenesis of uterine leiomyomas: a review // Environ. Health. Perspect. — 2003. — Vol. 111. — P. 1037–1054.][15. Oestrogen receptor-alfa gene polymorphism is associated with endometriosis, adenomyosis and leiomyomata / Kitawaki J. [et al.] // Hum. Reprod. — 2001. — Vol. 16. — P. 51–55.][16. Ovarian carcinoma-associated TaqI restriction fragment length polymorphism in intron G of the progesterone receptor gene id due to an Alu sequence insertion / Rowe S. M. [et al.] // Cancer Res. — 1995. — Vol. 55. — P. 2743–2745.][17. PROGINS Alu sequence insertion is associated with hyperprolactinaemia but not leiomyoma susceptibility / Hsieh Y. Y. [et al.] // Clin. Endocrinol. — 2005. — Vol. 62, № 4. — P. 492–497.][18. Sambrook J., Fritsch E. F., Maniatis T. Molecular cloning. A laboratory manual. — New York: Cold Spring Harbor Laboratory Press, 2001. — P. 1–245.]